Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 140 (planned)
- Started
- Jul 20, 2025
- Main results expected
- Oct 26, 2031
- Fully finished
- Oct 26, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
Measured over: Up to approximately 21 days
Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs)
Measured over: Up to approximately 74 months
Safety Lead In Phase: Number of participants who discontinue study treatment due to an AE
Measured over: Up to approximately 74 months
Efficacy Phase: Number of participants who experience one or more DLTs
Measured over: Up to approximately 21 days
Efficacy Phase: Number of participants who experience one or more AEs
Measured over: Up to approximately 74 months
Efficacy Phase: Number of participants who discontinue study treatment due to an AE
Measured over: Up to approximately 74 months
Efficacy Phase: Objective Response Rate (ORR)
Measured over: Up to approximately 74 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07049926 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC